IsoRay, Inc. (ISR)
| Market Cap | 99.89M |
| Revenue (ttm) | 9.62M |
| Net Income (ttm) | -3.52M |
| Shares Out | 122.57M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $0.699 |
| Previous Close | $0.706 |
| Change ($) | -0.008 |
| Change (%) | -1.08% |
| Day's Open | 0.710 |
| Day's Range | 0.690 - 0.720 |
| Day's Volume | 393,010 |
| 52-Week Range | 0.352 - 2.810 |
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 6.56%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Revenue Increased 10% Sequentially Record Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conference Call is Thursday, May 13 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Thursday, May 13 at 4:30 p.m. ET/1:30 p.m. PT
RICHLAND, Wash., April 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Donna Fort has been appointed V...
RICHLAND, Wash., March 31, 2021 (GLOBE NEWSWIRE) -- A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray's Cesi...
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -0.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Conference Call is Tuesday, February 9, 2021 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, February 9, 2021 at 4:30 p.m. ET/1:30 p.m. PT
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
There's an old saying that 'gaps refill'. And that means that these 7 penny stock Bubbles may be about to burst.
RICHLAND, Wash., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator powering expanding treatment options throughout the b...
Alkido Pharma (NASDAQ: AIKI) shares are trading higher after the company announced it executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications. AIkido...
Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Cancers At World's Premier Radiation Oncology Society Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Canc...
IsoRay, Inc. (ISR) CEO Lori Woods on Q1 2021 Results - Earnings Call Transcript
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -21.32%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Revenue Increased 3% Year-Over-Year
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conference Call is Tuesday, November 10, 2020 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, November 10, 2020 at 4:30 p.m. ET/1:30 p.m. PT
RICHLAND, Wash., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding trea...
IsoRay, Inc. (ISR) CEO Lori Woods on Q4 2020 Results - Earnings Call Transcript
IsoRay (ISR) delivered earnings and revenue surprises of -100.00% and -17.73%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Record Full Year Revenue and Gross Profit Full Year Revenue Increased 32% Year-Over-Year Record Full Year Revenue and Gross Profit Full Year Revenue Increased 32% Year-Over-Year
RICHLAND, Wash., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options througho...
Conference Call is Thursday, September 17, 2020, at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Thursday, September 17, 2020, at 4:30 p.m. ET/1:30 p.m. PT
Trial Will Evaluate Use of Pembrolizumab, Known as Keytruda®*, With Cesium-131 and Surgical Resection Trial Will Evaluate Use of Pembrolizumab, Known as Keytruda®*, With Cesium-131 and Surgical Resection
IsoRay (ISR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
RICHLAND, Wash., June 02, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR) today announced that the results of a new ten year study show positive outcomes for low-risk and intermediate-ri...
IsoRay, Inc. (ISR) CEO Lori Woods on Q3 2020 Results - Earnings Call Transcript
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 4.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Record Revenue and Gross Profit Revenue Increased 50% Year-Over-Year Record Revenue and Gross Profit Revenue Increased 50% Year-Over-Year
RICHLAND, Wash., May 12, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR) today announced that the Centers for Medicare and Medicaid Services (CMS) has approved 64 ICD-10-PCS billing codes...
IsoRay (ISR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
IsoRay Is Set For Further Growth
IsoRay (ISR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
IsoRay, Inc. (ISR) CEO Lori Woods on Q2 2020 Results - Earnings Call Transcript
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -7.70%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
IsoRay: Turned Around And Growing
Bundled Treatment Program Provides New Opportunities For Treating Physicians and Patients Facing Limited Options Bundled Treatment Program Provides New Opportunities For Treating Physicians and Patients...
IsoRay Likely Has Further To Rise
IsoRay (ISR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
IsoRay, Inc. (ISR) CEO Lori Woods on Q1 2020 Results - Earnings Call Transcript
IsoRay (ISR) delivered earnings and revenue surprises of 50.00% and 4.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Isoray, Inc. (NYSE AMERICAN: ISR) announced today that it will demonstrate its latest products at the American Brachytherapy Society’s (ABS) annual prostate brachytherapy workshop. The workshop is sche...
IsoRay, Inc. (ISR) CEO Lori Woods on Q4 2019 Results - Earnings Call Transcript
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 5.71%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Record Full Year Revenue Driven by 27% Growth in the Company’s Core Prostate Brachytherapy
Overall Ten-Year Biochemical Success Rate for Entire Group Was 96.2%Largest and Longest Followed Series of Cesium-131 Treated Patients Reported to Date
RICHLAND, WASHINGTON, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throug...
About ISR
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which pri... [Read more...]
| Industry Medical Instruments & Supplies | Founded 1983 |
| CEO Dwight Babcock | Employees 53 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol ISR |
Financial Performance
In 2020, IsoRay's revenue was $9.68 million, an increase of 32.35% compared to the previous year's $7.31 million. Losses were -$3.45 million, -33.01% less than in 2019.
Analyst Forecasts
According to 3 analysts, the average rating for IsoRay stock is "Strong Buy." The 12-month stock price forecast is 2.17, which is an increase of 210.67% from the latest price.